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Abstract: Background: Elevated levels of irritability are reported to occur in a number of neurological
conditions, including Huntington’s disease (HD), a genetic neurodegenerative disorder. Snaith’s Irritability
Scale (SIS) is used within HD research, but no psychometric evaluation of this instrument has previously been
undertaken. Therefore, the current study aimed to analyze the factor structure of this scale among an HD
population.
Methods: Exploratory and confirmatory factor analysis were used to examine the structural properties of SIS
using responses from 1,264 HD gene expansion carriers, across 15 European countries, who were engaged in
the REGISTRY 3 study.
Results: An exploratory factor analysis of a subsample of the data suggested a two-factor interpretation of
the data comprising “temper” and “self-harm.” Eight possible models were tested for goodness of fit using
confirmatory factor analysis. Two bifactor models, testing general and group factors in the structure of the
scale, provided an equivocal “good” fit to the data. The first comprised a general irritability factor and two
group factors (as originally proposed using SIS): outward irritability and inward irritability. The second
comprised a general irritability factor and two group factors (as proposed by the exploratory factor analysis):
temper and self-harm. The findings from both models suggested that the loadings of items were higher on
the general factor.
Conclusions: Bifactor models are proposed to best consider the structure of the SIS, with findings suggesting
that an overall score should be used to measure irritability within HD populations.
Irritability is often reported in people with a variety of neuro-
logical conditions, including Parkinson’s disease,1 Huntington’s
disease (HD),2 Gilles de la Tourette syndrome,3 and traumatic
brain injury.4 Irritability is understood as a temporary mood state
characterized by impatience, intolerance, and poorly controlled
anger;5 it may result in verbal or behavioral outbursts, although
the mood may be present without these observed manifestations,
is subjectively unpleasant, and can be brief or prolonged.6
Although irritability has not been the subject of significant
empirical research across both clinical and normative samples, it
warrants further study given that it has important clinical impli-
cations. For example, among people with mental health
difficulties, irritability is associated with poorer quality of life,
higher suicidal ideation, and a greater history of suicide attempts.7
Also, those who report irritable mood states are more likely to
experience mood disorders, anxiety and impulse-control disor-
ders, drug dependence, and a higher prevalence of fatigue.8 Given
these implications, it is important that clinicians and researchers
accurately identify and monitor irritability in order for complex
problems to be understood and managed effectively.7
In terms of HD, an inherited movement disorder with cogni-
tive decline and emotional difficulties, irritability is reported
across all stages of the disease, including the premotor manifest
period (i.e., before clinical diagnosis of HD).9–11 The
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prevalence of irritability among HD gene expansion carriers
varies across studies from 38% to 73%.2,12 Furthermore,
although irritability can correlate with other emotional difficul-
ties in HD, such as depression and anxiety,13 it demonstrates a
distinct pattern of increasing severity among premotor symp-
tomatic carriers as they become closer to motor onset, com-
pared with these other difficulties.11,14,15 Moreover, among
people with HD, irritability is more closely related to aggression
than other difficulties, such as depression, apathy, and anxi-
ety.12,16–19 This relationship with aggression, and thus the
potential risk of causing harm to others, has highlighted irri-
tability as a clinically and socially important construct to be
studied among those with HD. Such consequences of irritable
mood may also impact on provision of care, increasing the like-
lihood of HD patients having to move into a nursing home,
rather than being managed in the community.20,21 Therefore,
the interpersonal manifestations of heightened irritability may
have a deleterious effect on caregivers,22 resulting in protective
factors, such as social support and positive relationships, becom-
ing jeopardized. In addition to the risk of causing harm to
others, there is the potential that facets of irritability in HD may
also have associations with the risk of causing harm to the self,23
though, as yet, this has received limited attention. For example,
irritability has been found to be higher among HD gene expan-
sion carriers with suicidal ideation than among those without,23
a finding consistent with studies of those with mental health
difficulties.5 However, no predictive relationship between irri-
tability and suicidality has been identified,23 but this may be
partly explained by the measure of irritability used, which has
focused on outward conceptualisations of irritability.23 Further
understanding of the structural relationship of different aspects
of irritability may help inform future studies examining relation-
ships between suicide risk and irritability factors (i.e., both out-
ward and inward expressions of irritable mood5).
Within the literature available, irritability has most commonly
been measured among HD gene expansion carriers using inter-
viewer-rated assessments, such as the Problem Behaviors Assess-
ment-HD18 and the United Huntington’s Disease Rating Scale
(UHDRS).24 Although interviewer-based measures are useful in
enabling assessment of mood among HD patients who may not
be fully aware of their difficulties, brief self-report assessments
offer benefits, such as being quick and easy to administer, with
no specific training required for administration. Self-assessment
may also reveal information that some individuals may find dif-
ficult to disclose in more-formal interview settings. Currently, a
self-reported measure of irritability used within the field of HD
research is the irritability subscale contained within the Irritabil-
ity, Depression, Anxiety Scale,5 which has been used indepen-
dently as an eight-item measure of irritability and is also
referred to as the Snaith Irritability Scale (SIS).25,26 Further-
more, the SIS is the only self-report measure of irritability cur-
rently used in large-scale longitudinal international HD studies,
for example, REGISTRY (http://www.euro-hd.net/html/
registry) and ENROLL-HD (https://www.enroll-hd.org/).
The U.S. National Institute of Neurological Disorders and
Stroke has recently highlighted the importance of validation
studies for HD patient-reported instruments, especially when
considering outcome measures for clinical trials;27 therefore, it is
necessary for psychometrically informed studies to be under-
taken. In terms of the psychometric structure of the SIS, the
recommended scoring of the scale comprises two factors: four
irritability items within the scale measuring outwardly expressed
irritability and the other four examining inwardly expressed irri-
tability.5 However, psychometric validation studies of this
instrument in clinical samples are limited, and no study has
examined the psychometric properties of this scale within an
HD population, including testing the assumption of the original
scale as a two-factor model.
In the field of psychometrics, higher-order solutions present
alternative theoretical approaches for examination of the factor
structure of a scale. Rather than simply identifying the number
of factors that emerge from an analysis of test items, higher-
order factor analytical models introduce the concept of a general
construct and consider its relation to group factors formed from
the items. Within this perspective, the central theoretical differ-
ence focuses on the presence of a general factor informing our
understanding of the constructs being considered. Within
higher-order factor models, typically two solutions are consid-
ered: second-order factor and bifactor models.28 Second-order
factor models present the relationship between the factors and
items portrayed using a hierarchical structure, with the variance
of all items (at the bottom of the hierarchy) being explained by
group factors (e.g., inward vs. outward irritability) and the
group factor variance being explained by a general latent factor
(e.g., general irritability). With a bifactor model, the explained
variance between the items is simultaneously considered
between both the general and group factors. First, a single com-
mon construct (e.g., general irritability) is suggested to explain
the shared variance between all of the items. Second, to recog-
nize the multidimensionality of the construct, group factors are
suggested (e.g., inward versus outward irritability), to also
explain some of the shared variance between the items (see
Fig. 1 for an illustration).
Inclusion of these models in understanding the factor struc-
ture of the SIS, if proved useful, may help inform treatment
approaches. For example, in terms of the use of the SIS as an
assessment tool, interventions could be informed by considera-
tion of inward and outward irritability as separate constructs,
with potential etiological differences between the two. In con-
trast, within a higher-order solution, the treatment would
additionally be informed by consideration of the etiology of a
general factor of irritability. There is good reason to propose
an underlying general factor of irritability in HD attributed to
the genetic heritability of the disease. A number of processes
could underpin a general irritability factor (that encompasses
both outward or inward manifestations of irritability) that
include the direct neuropathological changes,29 cognitive
appraisals regarding having HD,30 and frustrations concerning
the overwhelming impact that the disease has on one’s life.31
Consequently, psychometric analysis using higher-order models
may help inform how interventions may be targeted, in terms
of understanding whether there are separate or related
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pathways that underpin the different facets of irritability among
people with HD.
The aim of the current study was to conduct the first factor
analysis study of the SIS within a large HD sample to explore
the latent structure within this population and evaluate the
structure against different proposed models of the SIS.
Materials and Methods
Sample and Measures
Data were obtained from the European HD Network (EHDN)
following approval from the Scientific and Bioethics Advisory
Committee. Our data request included all SIS assessments avail-
able from the REGISTRY 3 project. REGISTRY is a multina-
tional, observational study examining the natural history of HD.
Because the initial data set included longitudinal data involving
repeated assessments of annual visits using the same participants
(n = 3,234), we excluded all except the participants’ last visit
(n = 1,474). We also excluded 210 respondents with incom-
plete irritability assessments, missing Total Functional Capacity
(TFC) scores (measure of functional ability, ranging from 0 to
13, with lower scores reflecting reduced capacity to undertake
daily living activities) or Total Motor Scores (TMS; measure of
different motor tasks, with higher scores indicating greater
motor impairment) from the UHDRS, and those whose cyto-
sine-adenine-guanine repeat was ≤39 (to exclude those without
the HD gene expansion).
The final cross-sectional sample comprised 1,264 participants
with the HD gene expansion, who completed the SIS between
24 June 2011 and 20 February 2014, from the following Euro-
pean countries (n in brackets): Austria (12), Belgium (8), Czech
Republic (3), Finland (4), France (303), Germany (287), Italy
(38), Netherlands (97), Norway (17), Poland (228), Portugal
(70), Spain (134), Sweden (5), Switzerland (7), and UK (51).
Across all countries, participants gave written informed consent
according to the full ethical approvals required for the REGIS-
TRY study. Of these participants, 52.8% were female and the
mean age of the sample at time of visit was 48.71 years (stan-
dard deviation [SD] = 13.73; range, 14–88).
To describe the clinical profile of the sample, we examined
TFC scores, disease stage32 and the TMS scores from the
UHDRS.24 In terms of the profile of the sample, the TFC
mean score was 8.54 (SD = 3.94; range, 0–13). Across the
total sample, the breakdown of participants in each stage of
HD was as follows (n in brackets): Premanifest (250), Stage I,
with TFC scores of 11 to 13 (276), Stage II with TFC scores
7 to 10 (311), Stage III with scores 3 to 6 (315), Stage IV
with TFC scores of 1 or 2 (101), and Stage V with a TFC




The number of participants (632) to variables (8) ratio exceeded
the recommended ratio for exploratory factor analysis (EFA) of
10:1, with a minimum number of participants of 150.33 Bar-
tlett’s test confirmed an EFA was appropriate for the sample (v2
[28] = 15,544.21; P < 0.001), and a Kaiser–Meyer–Olkin test
(0.83) indicated sufficient participants: item ratio of 79:1. Pre-
liminary analyses of the scores on the items of the SIS demon-
strated that seven items fell outside the criterion for a univariate
Figure 1 Standardized loadings (with measurement error terms in parenthesis) for the eight-item SIS bifactor structure with general
irritability and outward and inward group factors.
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normal distribution of between 1.34 Therefore, a principal-
axis EFA was conducted.35
Parallel analysis (where eigenvalues are compared to those
calculated from purely random data) is the most appropriate
and accurate method for determining the number of fac-
tors.35,36 Within this analysis, the third eigenvalue (3.60, 1.13
and 0.77) failed to exceed the third mean eigenvalue (1.17,
1.11, and 1.06) calculated from 1,000 generated datasets with
501 cases and eight variables. This suggested a two-factor solu-
tion (with the factors accounting for 44.94% and 14.22% of
the variance, respectively). Loadings were assessed against the
thresholds of 0.32 (poor), 0.45 (fair), 0.55 (good), 0.63 (very
good), and 0.71 (excellent)37 and are presented in Table 1. In
terms of loadings above 0.45, the first factor comprises six
items that represent “temper,” encompassing inward and out-
ward expressions of irritability, such as “lose temper” and “feel
like slamming doors” (items are abbreviated because of copy-
right). The second factor comprises two items referring to self-
harm, “feel like harming myself” and “hurting myself occurs
to me.”
A correlation between the two factors was r = 0.57, suggest-
ing shared variance of 32.5%. The Cronbach’s alpha coeffi-
cients38 for: the eight items was a = 0.82; for the six items,
a = 0.80; and for the two items, a = 0.76. These statistics
exceed the criterion of a > 0.70 as “good.”39,40
Confirmatory Factor Analysis
To explore the structural validity of the SIS, a series of compar-
isons using confirmatory factor analysis (CFA) was performed
using AMOS 22 software with the second sample data. A focus
of CFA is to demonstrate the incremental value of proposed
models.41 Eight possible models were tested for goodness of fit.
The first two were unidimensional models representing an
underlying latent factor structure of general irritability (1) for
the eight items of the SIS and (2) the six items that loaded on
the first factor in the EFA. The third model tested was the pro-
posed original two-factor structure for the SIS, inward and out-
ward factors. The fourth model was the proposed two-factor
structure resulting from our EFA of the SIS, temper and self-
harm factors. The remaining models tested higher-order
solutions for the data. The fifth and sixth models were second-
order factor models in which general irritability formed the top
level of a hierarchy in which inward versus outward (model 5)
and temper and self-harm irritability (model 6) were group fac-
tors. The seventh and eighth models were higher-order bifactor
models proposing a single common construct (general irritabil-
ity) while recognizing the multidimensionality of the construct;
inward and outward (model 7) and temper and self-harm irri-
tability (model 8).
To assess the goodness of fit of the data, we used six statis-
tics recommended by Hu and Bentler42 and Kline:43 the chi-
square (v2); the relative chi-square (CMIN/DF); the compara-
tive fit index (CFI); the non-normed fit index (NNFI); the
root mean square error of approximation (RMSEA); and the
standardized root mean square residual (SRMR). The follow-
ing criteria was used to assess whether the model fit to the
data was adequate (noting that the chi-square test was likely to
be significant because of large sample size):44 (1) CMIN/DF
must fall between 5 and 2 to be “acceptable” and be less than
2 to be “good”; (2) that the CFI and NNFI should exceed
0.90 to be “acceptable” and exceed 0.95 to be “good”; (3)
that the RMSEA should not exceed 0.08 to be “acceptable”;
and be under 0.06 to be “good”; and (4) SRMR values less
than 0.08 are “acceptable” and less than 0.05 to be
“good.”42,43,45
The goodness-of-fit statistics for the eight models are pre-
sented in Table 2. For the unidimensional, two-factor and sec-
ond-order models, the large majority of the goodness-of-fit
statistics did not meet all the aforementioned criteria for accept-
ability, and therefore the models did not present an adequate
explanation of the data. The bifactor models presented relative
chi-square and RMSEA statistics that were acceptable and CFI,
NNFI, and SRMR goodness-of-fit statistics all exceeding the
“good” criteria. The findings for the bifactor models also
demonstrate improved CFI statistics over the other models, as
indicated by changes in CFI (DCFI) being >0.01.
The standardized loadings (with measurement error terms in
parenthesis) for both suggested bifactor structures with general
and group factors are presented in Figures 1 and 2. A number
of statistics were used to examine the relative relationship
between the general and group factors. In terms of the original
two factors of the SIS (inward and outward), the variance
accounted for the general factor in this model was 64.2%, with
inward and outward group factors explaining 13.7% and 22.1%,
respectively. In terms of salience of loading on the factors, the
mean loadings were higher on the general factor (m = 0.59)
than on the group factors (m = 0.41). The more-traditional
reliability estimates for the general and group factors were good:
general factor a = 0.83; omega total = 0.89; outward group
factor, a = 0.78; omega total = 0.79; inward group factor,
a = 0.77; omega total = 0.86. However, the omega hierarchical
coefficient, which estimates the reliability with the effect of all
the other factors removed, was low for the group factors (out-
ward, omega hierarchical = 0.38; inward, omega hierarchi-
cal = 0.17) and was only acceptable for the general irritability
factor (omega hierarchical = 0.71).
TABLE 1 EFA (principal axis factoring extraction with promax rota-
tion) of the eight irritability items
Factor
1 2
1. “lose temper” 0.82 0.10
2. ”patient with people” (R) 0.57 0.06
3. “angry with myself” 0.49 0.22
4. “harming myself” 0.03 0.73
5. “hurting myself” 0.08 0.86
6. “lose control and hurt someone” 0.59 0.01
7. “feel like slamming doors or
banging about”
0.69 0.01
8. “annoyed with myself” 0.50 0.24
Key: (R) = reversed.
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The findings were similar in terms of the scoring derived
from the EFA (i.e., temper and self-harm). Variance accounted
for the general factor in this model was 67.3%, with inward and
outward group factors explaining 12.1% and 20.5%, respec-
tively. In terms of salience of loading on the factors, the means
loadings were higher on the general factor (m = 0.62) than on
the group factors (m = 0.39). The more-traditional reliability
estimates for the general and group factors were good: general
factor, a = 0.83; omega total = 0.90; temper group factor,
a = 0.80; omega total = 0.87; self-harm group factor, a = 0.84;
omega total = 0.86. However, the omega hierarchical coeffi-
cient was low for the group factors (temper, omega hierarchi-
cal = 0.15; self-harm, omega hierarchical = 0.54) and was only
acceptable for the general irritability factor (omega hierarchi-
cal = 0.75).
Discussion
Among a large European study of HD expansion carriers, we
found that a bifactor interpretation is a structurally valid method
of interpreting scores on the SIS, thus retaining the notion of
an overall assessment of irritability, while recognizing the multi-
dimensionality of the SIS. Two different considerations of the
multidimensionality of the SIS were explored within the cur-
rent study. The first was Snaith’s original conceptualization of
outward and inward irritability5 and the second was suggested
by findings from an EFA of “temper” and “self-harm” items.
When these different conceptualizations of irritability were
assessed further using CFA, we found that, regardless of
whether the formulation comprised inward/outward dimensions
or temper/self-harm dimensions, the statistical solution sug-
gested that an overall score was the most stable. Therefore,
based on the current findings, the primary recommendation is
that all SIS items are used to produce an overall measure of
irritability.
These findings have relevance for the measurement and treat-
ment of irritability in people with HD. A higher-order bifactor
model suggests the accommodation of both general factor and
group factors of irritability, with our findings suggesting that an
emphasis should be made on the former. This implies a change
Figure 2 Standardized loadings (with measurement error terms in parenthesis) for the eight-item SIS bifactor structure with general
irritability and temper and self-harm group factors.
TABLE 2 CFA fit statistics for the different models proposed for the SIS
v
2
df P CMIN/DF CFI NNFI RMSEA SRMR
Unidimensional (eight items) 475.31 20 <0.000 23.77 0.753 0.654 0.190 0.088
Unidimensional (six items) 150.62 9 <0.000 16.74 0.875 0.791 0.158 0.067
Two factors (inward/outward) 265.31 19 <0.000 13.96 0.866 0.803 0.129 0.143
Two factors (temper/self-harm) 265.31 19 <0.000 13.96 0.866 0.803 0.129 0.143
Second-order (inward/outward) 265.31 19 <0.000 13.96 0.866 0.803 0.143 0.086
Second-order (temper/self-harm) 181.81 19 <0.000 9.57 0.912 0.870 0.117 0.060
Bifactor (inward/outward) 41.34 12 <0.000 3.45 0.983 0.963 0.062 0.025
Bifactor (temper/self-harm) 41.34 12 <0.000 3.45 0.984 0.963 0.062 0.025
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in the understanding of what scores on the SIS represent among
people with HD. It may not be enough simply to see the SIS
as measuring two separate factors (inward and outward) or a
unidimensional construct. Rather, whereas it is possible to rec-
ognize multidimensional aspects of the SIS, scores on the SIS
are also informed by a general SIS factor. This suggests that,
alongside group factors, a general factor of irritability may need
to be considered. For example, this might be hypothesized as
neuropathological changes that occur in HD having an underly-
ing influence on SIS scores. Recent support for this hypothesis
was provided by the TRACK-HD study that identified irritabil-
ity to be associated with a distinct pattern of microstructural
changes in the posterior tracts of the left hemisphere.29 The
researchers suggested that irritability may arise in situations
when someone with HD may be stretched cognitively and is
consistent with another Track-on study suggesting that left
hemispheric deterioration appears to occur first in HD, with
compensation by the right hemisphere as illustrated by func-
tional MRI.46 Alternatively, generalized irritability may be
underpinned by other changes endemic to the experience of
chronic illness, such as cognitions that are activated in a range
of contexts and might lead to different behavioral/emotional
outcomes depending on a range of individual or situational fac-
tors inherent to that specific context.
These findings and suggestions have considerable significance,
given that the study of irritability in HD, and other neurological
disorders, is still in its infancy. The identification of inward and
outward dimensions or temper and self-harm aspects of irritabil-
ity, within a general factor of irritability, may be important in
further considerations of irritability using the SIS. For example,
researchers may wish to examine how the different formulations
of irritability are associated with clinical risk, especially in the
context of other factors in HD that may contribute to complex
clinical presentations (such as executive functioning difficulties
of heightened impulsivity, poor risk assessment, and reduced
problem-solving strategies47,48). The clinical risks that could be
associated with such conceptualizations of irritability may
include physical aggression, risk of harming self, or heightening
risk of being harmed by other people (e.g., through losing one’s
temper easily with other people). Future research might wish to
look at whether the aspects of irritability, as measured by the
different formulations of the SIS, has any predictive utility
regarding such risk behaviors among people with HD. Further
consideration might be given to the various aspects of HD that
potentially contribute to the general factor of irritability across
the different stages of the disease. These range from biological
contributions, such as white matter changes,29 to neuropsycho-
logical aspects, such as cognitive overload,29 to cognitive apprai-
sals around having HD,30 to frustrations over reduced
functional, motor and cognitive abilities, and changes in per-
sonal relationships.31
Despite these new findings, we also identify a number of
potential limitations. The current REGISTRY sample may not
be representative of the HD population as a whole. For
instance, participants within this study who were in the more-
advanced stages of the disease may have been less likely to have
engaged in the research. Also, the data were collected from a
Europe-wide sample involving translated versions of instru-
ments. Therefore, in studying the data as a whole, we did not
consider how expressions of irritability are construed differently
cross-culturally, which suggests caution in applying the general
findings to any single European sample.
In summary, this article outlines the first factor analysis study
of scores obtained from the SIS across a large European sample
of an HD population. The study provides evidence for two
bifactor models and suggests a change is needed in how we
should conceptually consider irritability in terms of both general
and group factors. Mindful that irritability may stem from a
general factor, we recommend that the SIS is best used as a
general measure of irritability among HD gene expansion
carriers.
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